Arca Biopharma Inc ABIO Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Hove Anders D

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Woosley Raymond L.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Grais Linda

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Mitchell Daniel J

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Conway Robert E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Keuer Thomas A

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

70,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Ozeroff Christopher David

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

55,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Bristow Michael R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

190,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Selby Brian L.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

55,000

Price:

--
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Conway Robert E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

10,000

Price:

$4.16

Filings by filing date

Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Hove Anders D

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Woosley Raymond L.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Grais Linda

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Mitchell Daniel J

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Conway Robert E

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

12,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Keuer Thomas A

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

70,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Ozeroff Christopher David

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

55,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Bristow Michael R

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

190,000

Price:

--
Dec 21, 2020 (filed on Dec 23, 2020)

Insider Name:

Selby Brian L.

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

55,000

Price:

--
Dec 18, 2020 (filed on Dec 21, 2020)

Insider Name:

Conway Robert E

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

P - Open market or private purchase

# or value acquired/disposed of:

10,000

Price:

$4.16

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	10170 Church Ranch Way, Suite 100 WESTMINSTER CO 80021
Tel:	N/A
Website:	arcabio.com
IR:	See website

Key People

Robert E. Conway Chairman of the Board	Michael R. Bristow President, Chief Executive Officer, Director	Thomas A. Keuer Chief Operating Officer
Christopher David Ozeroff Senior Vice President, General Counsel, Secretary	Brian L. Selby Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance

Business Overview

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Financial Overview

For the nine months ended 30 September 2020, ArcaBiopharma Inc revenues was not reported. Net loss increased8% to $4.6M. Higher net loss reflects Other -Research anddevelopment increase of 27% to $1.8M (expense), Interestand other income decrease of 80% to $27K (income), RentalExpense increase of 40% to $73K (expense). Basic Earningsper Share excluding Extraordinary Items increased from-$3.75 to -$1.88.

Employees:	9 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	N/A
Annual revenue (TTM):	$0.00M as of Sep 30, 2020
EBITDA (TTM):	-$5.91M as of Sep 30, 2020
Net annual income (TTM):	-$5.84M as of Sep 30, 2020
Free cash flow (TTM):	-$5.90M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	9,321,470 as of Oct 30, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Arca Biopharma Inc (OQ:ABIO)